The Eaton Standard.

Nine volumes into asking cannabis brands what is actually in the package, we have a rough ranking. FK+ named thirteen botanicals and disclosed none of them. BRĒZ disclosed its lion's mane in wet mushroom weight so 33 milligrams could read as 2,200. RIVR published every milligram and took a mixed review for it, which we said at the time was the trade we wanted more brands to make.

Eaton Botanicals goes further than any of them. On every gummy product page, the brand publishes an itemised per-piece list: reishi 24 mg, L-theanine 50 mg, magnolia bark 150 mg, turmeric 250 mg, chasteberry 25 mg. Full ingredient declarations. An allergen line. And — unusually — a public, batch-indexed certificate library going back to 2023, with terpene panels running 28 to 29 analytes where New York's mandatory minimum is twenty.

They also publish the terpene results for the gummies, where the numbers are effectively zero. One reads 0.0333% total terpenes. There is no regulation compelling that and no marketing advantage in it. Publishing a null result you were never asked for is the single most credible thing a brand in this category can do, and we want to say so before anything else in this piece.

So this review divides cleanly, and not along the line you might expect. The disclosure is excellent. What the disclosure reveals is more complicated. And on one product line — the pre-rolls — the company abandons its own standard entirely, on precisely the ingredient the product is named and sold for.

Eight gummies, and what is in them.

All eight are 20-count tins, one gummy per serving, $32 at standard price. Every SKU sits comfortably inside New York's edible limits — 10 mg THC per serving, 100 mg per package — and most sit at half of them.

Golden Ticket is the one edible that reverts to prose-only botanical description · $38–40

Label accuracy checks out where we could test it. The Fixer Upper batch EB-G-MG-007 certificate from DRS Testing in Buffalo reports 4.74 mg Δ9-THC and 4.88 mg CBD against a 5/5 mg label — 94.8% and 97.6%, both comfortably inside New York's 85–115% band.

One sentence that the data answers precisely.

Eaton's edibles page states that its products are made "using the recommended daily allowance of adaptogens and supplements." The FAQ, asked directly how much of each ingredient is used, answers that ingredients are dosed "effectively" and moves on without a number — which is odd, given that the numbers are published one click away.

Recommended Daily Allowance is a defined regulatory term. It exists for vitamins and minerals. It does not exist for reishi, chaga, cordyceps, turkey tail, lion's mane, magnolia bark, astragalus, chasteberry or mullein — there is no RDA for any of them, because they are not essential nutrients.

Run the claim against the catalogue and it resolves with unusual clarity. In the one category where RDA is a real number, Eaton hits it exactly: B6 at 1.3 mg is the adult RDA to the decimal place, three times over. In the category the sentence is actually advertising — adaptogens — the term has no referent, and the delivered doses average five percent of the nearest equivalent benchmark.

And then the pre-rolls.

Eaton sells two pre-roll lines, Little Pandas and Chairlifts, both built on 0.35 g minis of cannabis flower blended with mullein leaf. The category page for them is headed "The One With The Mullein." Mullein is the differentiator. It is the reason the product exists as a separate line.

The entire published disclosure for that ingredient, on both product pages, is one line: "Ingredients: Cannabis flower, organic mullein leaf." No milligram figure. No percentage of the blend. No ratio. There is no "Inside the Tin" panel on the pre-roll pages at all — the format the brand uses everywhere else in its catalogue simply is not there.

Nor is it tested. Every pre-roll certificate of analysis lists the sample type as "Flower." The documents characterise the cannabis. Nothing in the certificate library measures, or even acknowledges, the mullein that a customer is actually inhaling.

The claim escalates across the site.

What makes this worth more than a paragraph is that the respiratory claim attached to that undisclosed ingredient does not stay in one place. It hardens as you move from the category page to the product page to the homepage.

The hedges — "known for," "can help," "could ease" — are present at the top of the funnel and gone at the bottom. By the product page the claim is in the plain indicative: mullein helps, supports, eases. On a combustion product. With the dose undisclosed and untested.

The marketing copy, and what New York's rules say.

New York amended its packaging and marketing regulations effective 3 December 2025, and the amended text is materially stricter than the version most secondary databases still serve. We are setting the rule and the copy side by side and drawing no legal conclusion — that determination belongs to the Office of Cannabis Management, not to us. But a reader evaluating this brand should see both.

Worth stating clearly on the other side: adding botanicals to a cannabis edible is expressly permitted in New York. §128.5(b)(1) contemplates "micronutrient, or herbal supplements" directly, and there is no numeric dose cap on any non-cannabis ingredient anywhere in Parts 123, 128, 129 or 130. Eaton is doing something the state has decided to allow. The question raised by the copy is about how it is described, not about whether the formulation is legitimate.

We would also note the structural point this series keeps returning to. The strictness runs backwards from where a consumer would expect. New York polices the claim aggressively and sets no floor on the dose. A brand may put 24 milligrams of reishi in a gummy and face no dose regulation whatsoever, while the sentence describing what the reishi does is tightly controlled. The result is a market where marketing language is the regulated surface and pharmacology is not.

The certificate library, and four things wrong with it.

Eaton maintains a genuinely strong public COA archive — four year folders from 2023 to 2026, organised by product and batch ID, full PDFs. Gummies go to DRS Testing in Buffalo; pre-rolls to MCR Labs New York in Utica, with terpene panels of 28–29 analytes against the state's 20-analyte minimum. New York requires only a scannable code on the package linking to a downloadable certificate; there is no central public database and no obligation to host a library at all. Eaton exceeds the requirement.

Four defects turned up in the archive itself.

And none of it reaches the shelf. Across every dispensary platform we checked — Dutchie, Blaze, Dispense, custom builds — no Eaton listing anywhere surfaces a lab name, batch ID, COA link or terpene profile. One menu offers a "View Lab Results" button that returns "No lab results available for this product." The best certificate archive in this series sits one click from nobody.

Three corporate details a reader should have.

Eaton does not currently manufacture its own products. The company holds four OCM licences, and both processor licences — OCM-PROC-25-000298 and OCM-PROC-26-000335 — are listed by the state as Non-Operational. The certificates name the actual manufacturer: Nowave LLC of Rochester, with some 2025 pre-roll work through Outcast Acres Farm. This is legal, common, and unremarkable in itself. It sits awkwardly against the site's "farm to formulation" framing, which is worth a question to the company.

One licensing claim does not survive checking. The About page states that "in 2022, Eaton Botanicals received one of the first Adult-Use cannabis cultivation licenses." OCM's own conditional-cultivator roster lists Eaton License LLC at OCM-AUCC-23-000301 — a 2023-series licence, roughly number 301 of about 306, near the end of the cohort. New York's first 52 adult-use conditional cultivator licences issued in April 2022 carry low 22-series numbers. Eaton is not among them.

The hemp claim, by contrast, checks out. Eaton's founders — Daniel Dolgin, formerly of the Office of the Director of National Intelligence, and Mark Justh, formerly of JPMorgan — did plant what a New York State Assembly press release of 3 July 2016 called the first hemp sown in New York "for the first time in 80 years," at JD Farms in Eaton. CNY Central covered it that September with Dolgin on camera. The precision caveat is that they did it as JD Farms principals; Eaton Botanicals as an adult-use brand did not exist until 2023. The sentence is true about the people rather than the company, which is a distinction the About page does not draw.

Two smaller inconsistencies for completeness: the About page gives the farm as "2500 acre," while the company's own otherwise word-for-word identical boilerplate elsewhere says 500 acres, and earlier trade coverage said 1,300 and 2,000-plus. And the pre-roll pages contradict themselves on format — Little Pandas described as "0.5 g" against its own certificate reading "0.35g 5 pack," and Chairlifts listed as both a 2-pack and a 3-pack on the same page.

What Eaton proves.

There is a version of this review that reads as a takedown, and it would be the wrong one. Eaton Botanicals discloses more than any brand we have examined. It publishes null results. It maintains a certificate archive the law does not require. Its cannabinoid labelling is accurate to within six percent on third-party assay. Two of its botanicals are dosed to the evidence.

Every critical finding in this piece — the 5% mushroom delivery, the RDA sentence, the B12 unit error — is available only because Eaton published the numbers. FK+ made a louder claim about dosing and we could not evaluate a single milligram of it. That asymmetry is the whole argument for disclosure, and Eaton is the strongest evidence for it we have found.

Which is exactly why the pre-rolls matter. The gap there is not capability, or cost, or a regulatory obstacle. Eaton has a template for documenting a botanical and uses it eight times over. It simply did not apply that template to the product it named after mullein, while making a claim about lung function in the indicative mood. One panel would close it.

We will revise this piece the day a mullein dose and a blend-inclusive certificate appear. On the evidence of everything else on that website, we would expect it to be a short wait.